6,320 results on '"Bombesin"'
Search Results
52. Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years.
- Author
-
Dalm S, Duan H, and Iagaru A
- Subjects
- Humans, Male, Radioisotopes therapeutic use, Receptors, Bombesin antagonists & inhibitors, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms radiotherapy, Radiopharmaceuticals therapeutic use, Positron-Emission Tomography methods
- Abstract
Each tumor has its own distinctive molecular identity. Treatment, therefore, should be tailored to this unique cancer phenotype. Theragnostics uses the same compound for targeted imaging and treatment, radiolabeled to an appropriate radionuclide, respectively. Gastrin-releasing peptide receptors (GRPRs) are overexpressed in prostate cancer, and radiolabeled GRPR antagonists have shown high diagnostic performance at staging and biochemical recurrence. Several GRPR-targeting theragnostic compounds have been developed preclinically. Their translation into clinics is underway with 4 clinical trials recruiting participants with GRPR-expressing tumors., Competing Interests: Disclosure The authors have nothing to disclose., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
53. 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
- Author
-
National Cancer Institute (NCI) and Andrei Iagaru, Associate Professor of Radiology
- Published
- 2017
54. PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer
- Published
- 2017
55. Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial
- Subjects
Prostate cancer -- Care and treatment ,Cancer -- Care and treatment ,Bombesin ,General interest ,News, opinion and commentary - Abstract
SYDNEY: Clarity Pharmaceuticals has issued the following news release: Clarity Pharmaceuticals (ASX: CU6) ('Clarity'), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes [...]
- Published
- 2023
56. Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial
- Subjects
Prostate cancer ,Cancer -- Care and treatment ,Bombesin ,Business ,News, opinion and commentary - Abstract
SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ('Clarity'), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and [...]
- Published
- 2023
57. Changes of Gastric Secretion after Bolus and Slow Intravenous Administration of Bombesin and Neurotensin.
- Author
-
TSALIS, Konstantinos, IOANNIDIS, Orestis, MARIORAKIS, Chrysovalantis, CHRISTIDIS, Panagiotis, LOUTZIDOU, Lydia, MANTZOROS, Ioannis, KOTIDIS, Efstathios, PRAMATEFTAKIS, Manousos George, OUZOUNIDIS, Nikolaos, and AGGELOPOULOS, Stamatios
- Subjects
- *
INTRAVENOUS therapy , *NEUROTENSIN , *SECRETION , *BODY weight , *GASTRIN , *GASTRIC bypass - Abstract
Objective: The aim of the present study was to evaluate the changes caused by intravenous administration of regulatory peptides, bombesin (BBS) and neurotensin (NT), on gastric secretion, serum gastrin, and plasma levels of bombesin-1ike immunoreactivity (BLI) and neurotensin. Materials and methods: Fourteen dogs underwent an upper gastrointestinal tract operation and a Pavlov pouch for the concentration of gastric fluids was formed. The experimental animals were divided into two groups. Peptides were given one month after the second operation and after fasting for 12 hours. In group A, the effects of BBS were studied after a rapid 1 µg/kg body weight dose and a slow 30΄ 0.5 μg/kg body weight dose administration intravenously. Correspondingly to group B the effects of NT were studied in the same way. Results: The rapid intravenous infusion of BBS caused a very significant increase in gastrin levels, BLI in plasma, volume and HCl of the gastric fluids. The same results, plus a significant decrease in gastric pH, were observed following slow intravenous infusion of BBS. Concerning the NT, rapid administration caused a significant decrease in the volume of gastric fluids. Slow NT administration of caused a significant reduction in gastric fluid volume and in HCl. On the contrary, pH was significantly increased. Conclusion: Bombesin increases plasma gastrin levels and HCl secretion. Neurotensin administration causes a decrease in HCl secretion without affecting gastrin levels in plasma. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
58. Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.
- Author
-
Moody, Terry W., Lee, Lingaku, Ramos-Alvarez, Irene, Iordanskaia, Tatiana, Mantey, Samuel A., and Jensen, Robert T.
- Subjects
CENTRAL nervous system tumors ,NEUROBLASTOMA ,DRUG target ,TUMORS in children ,TUMORS - Abstract
G-protein-coupled receptors (GPCRs) are increasingly being considered as possible therapeutic targets in cancers. Activation of GPCR on tumors can have prominent growth effects, and GPCRs are frequently over-/ectopically expressed on tumors and thus can be used for targeted therapy. CNS/neural tumors are receiving increasing attention using this approach. Gliomas are the most frequent primary malignant brain/CNS tumor with glioblastoma having a 10-year survival <1%; neuroblastomas are the most common extracranial solid tumor in children with long-term survival<40%, and medulloblastomas are less common, but one subgroup has a 5-year survival <60%. Thus, there is an increased need for more effective treatments of these tumors. The Bombesin-receptor family (BnRs) is one of the GPCRs that are most frequently over/ectopically expressed by common tumors and is receiving particular attention as a possible therapeutic target in several tumors, particularly in prostate, breast, and lung cancer. We review in this paper evidence suggesting why a similar approach in some CNS/neural tumors (gliomas, neuroblastomas, medulloblastomas) should also be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
59. Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma.
- Author
-
Castellone, M, Laukkanen, M, Teramoto, H, Bellelli, R, Alì, G, Fontanini, G, Santoro, M, and Gutkind, J
- Subjects
Animals ,Bombesin ,Boronic Acids ,Bortezomib ,Cisplatin ,GTP-Binding Protein alpha Subunits ,G12-G13 ,GTP-Binding Protein alpha Subunits ,Gq-G11 ,HEK293 Cells ,Hedgehog Proteins ,Humans ,Lung Neoplasms ,Mice ,NIH 3T3 Cells ,Oncogene Proteins ,Pyrazines ,Receptors ,Bombesin ,Signal Transduction ,Small Cell Lung Carcinoma ,Trans-Activators ,Zinc Finger Protein GLI1 - Abstract
Small cell lung carcinoma (SCLC) often features the upregulation of the Sonic hedgehog (Shh) pathway leading to activation of Gli transcription factors. SCLC cells secrete bombesin (BBS)-like neuropeptides that act as autocrine growth factors. Here, we show that SCLC tumor samples feature co-expression of Shh and BBS-cognate receptor (gastrin-releasing peptide receptor (GRPR)). We also demonstrate that BBS activates Gli in SCLC cells, which is crucial for BBS-mediated SCLC proliferation, because cyclopamine, an inhibitor of the Shh pathway, hampered the BBS-mediated effects. BBS binding to GRPR stimulated Gli through its downstream Gαq and Gα₁₂/₁₃ GTPases, and consistently, other Gαq and Gα₁₃ coupled receptors (such as muscarinic receptor, m1, and thrombin receptor, PAR-1) and constitutively active GαqQL and Gα₁₂/₁₃QL mutants stimulated Gli. By using cells null for Gαq and Gα₁₂/₁₃, we demonstrate that these G proteins are strictly necessary for Gli activation by BBS. Moreover, by using constitutively active Rho small G-protein (Rho QL) as well as its inhibitor, C3 toxin, we show that Rho mediates G-protein-coupled receptor (GPCR)-, Gαq- and Gα₁₂/₁₃-dependent Gli stimulation. At the molecular level, BBS caused a significant increase in Shh gene transcription and protein secretion that was dependent on BBS-induced GPCR/Gαq-₁₂/₁₃/Rho mediated activation of nuclear factor κB (NFκB), which can stimulate a NF-κB response element in the Shh gene promoter. Our data identify a novel molecular network acting in SCLC linking autocrine BBS and Shh circuitries and suggest Shh inhibitors as novel therapeutic strategies against this aggressive cancer type.
- Published
- 2015
60. Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy
- Author
-
Terry W. Moody, Lingaku Lee, Irene Ramos-Alvarez, Tatiana Iordanskaia, Samuel A. Mantey, and Robert T. Jensen
- Subjects
bombesin ,gastrin releasing peptide ,neuromedin B ,glioma ,neuroblastoma ,medulloblastoma ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
G-protein-coupled receptors (GPCRs) are increasingly being considered as possible therapeutic targets in cancers. Activation of GPCR on tumors can have prominent growth effects, and GPCRs are frequently over-/ectopically expressed on tumors and thus can be used for targeted therapy. CNS/neural tumors are receiving increasing attention using this approach. Gliomas are the most frequent primary malignant brain/CNS tumor with glioblastoma having a 10-year survival
- Published
- 2021
- Full Text
- View/download PDF
61. Gastrointestinal Hormones
- Author
-
Welcome, Menizibeya Osain and Welcome, Menizibeya Osain
- Published
- 2018
- Full Text
- View/download PDF
62. Research Study Findings from BC Cancer Research Institute Update Understanding of Cancer Imaging [Synthesis and Evaluation of Novel 68Ga-Labeled [D-Phe6,Leu13psThz14]bombesin(6-14) Analogs for Cancer Imaging wi.
- Abstract
A recent research study conducted by the BC Cancer Research Institute in Vancouver, Canada, has focused on cancer imaging and the potential use of Gastrin-releasing peptide receptor (GRPR) as a target for cancer diagnosis and therapy. The study synthesized and evaluated four derivatives of a GRPR-targeted antagonist tracer and found that one derivative, Ga-LW01158, showed promising results in detecting GRPR-expressing tumors with positron emission tomography (PET). The derivative had high tumor uptake and good tumor-to-background imaging contrast, making it a potential candidate for detecting GRPR-expressing lesions. The study was supported by the Canadian Institutes of Health Research and the China Scholarship Council. [Extracted from the article]
- Published
- 2024
63. An Insight into Neuropeptides Inhibitors in the Biology of Colorectal Cancer: Opportunity and Translational Perspectives
- Author
-
Ankit Srivastava, Deeksha Rikhari, Biswajita Pradhan, Kaushik Kumar Bharadwaj, Antonio Gaballo, Alessandra Quarta, Mrutyunjay Jena, Sameer Srivastava, and Andrea Ragusa
- Subjects
neuropeptide ,receptor ,inhibitors ,cancer ,therapeutic agents ,bombesin ,Technology ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Biology (General) ,QH301-705.5 ,Physics ,QC1-999 ,Chemistry ,QD1-999 - Abstract
Neuropeptides are mainly secreted from the human central and peripheral nervous systems. Neuropeptides bind to its cognate rhodopsin-like G-protein coupled receptor (GPCR) and perform various physiological functions. Conventional cancer treatments in clinical practice still present many drawbacks due to the lack of selectivity toward the target cell, drug-resistance, and side-effects, thus pushing for the development of new therapeutic agents and therapies. Recent research suggests that neuropeptides influence cancer cell proliferation, invasion, metastasis, and angiogenesis and, therefore, they could be exploited as a target for novel anticancer therapies. Very recently, targeted approaches that inhibit neuropeptides and their associated receptors are being developed in cancer treatment. This review focuses on various neuropeptides and their potential utility as drug targets by different inhibitors as a recently identified approach to cancer prevention, with particular emphasis on colorectal cancer.
- Published
- 2022
- Full Text
- View/download PDF
64. The gastrin-releasing peptide/bombesin system revisited by a reverse-evolutionary study considering Xenopus.
- Author
-
Hirooka, Asuka, Hamada, Mayuko, Fujiyama, Daiki, Takanami, Keiko, Kobayashi, Yasuhisa, Oti, Takumi, Katayama, Yukitoshi, Sakamoto, Tatsuya, and Sakamoto, Hirotaka
- Subjects
- *
GASTRIN-releasing peptide , *XENOPUS , *BOMBESIN , *GENE expression , *IMMUNOHISTOCHEMISTRY - Abstract
Bombesin is a putative antibacterial peptide isolated from the skin of the frog, Bombina bombina. Two related (bombesin-like) peptides, gastrin-releasing peptide (GRP) and neuromedin B (NMB) have been found in mammals. The history of GRP/bombesin discovery has caused little attention to be paid to the evolutionary relationship of GRP/bombesin and their receptors in vertebrates. We have classified the peptides and their receptors from the phylogenetic viewpoint using a newly established genetic database and bioinformatics. Here we show, by using a clawed frog (Xenopus tropicalis), that GRP is not a mammalian counterpart of bombesin and also that, whereas the GRP system is widely conserved among vertebrates, the NMB/bombesin system has diversified in certain lineages, in particular in frog species. To understand the derivation of GRP system in the ancestor of mammals, we have focused on the GRP system in Xenopus. Gene expression analyses combined with immunohistochemistry and Western blotting experiments demonstrated that GRP peptides and their receptors are distributed in the brain and stomach of Xenopus. We conclude that GRP peptides and their receptors have evolved from ancestral (GRP-like peptide) homologues to play multiple roles in both the gut and the brain as one of the 'gut-brain peptide' systems. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
65. Roles of glutamate, substance P, and gastrin-releasing peptide as spinal neurotransmitters of histaminergic and nonhistaminergic itch
- Author
-
Akiyama, Tasuku, Tominaga, Mitsutoshi, Takamori, Kenji, Carstens, Mirela Iodi, and Carstens, E
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Prevention ,6-Cyano-7-nitroquinoxaline-2 ,3-dione ,Action Potentials ,Animals ,Antirheumatic Agents ,Bombesin ,Chloroquine ,Drug Combinations ,Excitatory Amino Acid Antagonists ,Ganglia ,Spinal ,Gastrin-Releasing Peptide ,Glutamic Acid ,Male ,Mice ,Mice ,Inbred C57BL ,Neurokinin-1 Receptor Antagonists ,Neurons ,Peptide Fragments ,Piperidines ,Pruritus ,Substance P ,Vesicular Glutamate Transport Protein 2 ,Gastrin-releasing peptide ,Glutamate ,Histamine ,Itch ,Scratching ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Anesthesiology ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
We investigated roles for substance P (SP), gastrin-releasing peptide (GRP), and glutamate in the spinal neurotransmission of histamine-dependent and -independent itch. In anesthetized mice, responses of single superficial dorsal horn neurons to intradermal (i.d.) injection of chloroquine were partially reduced by spinal application of the α-amino-3-hydroxy-5-methyl-4-isoxazole proprionate acid (AMPA)/kainate antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX). Co-application of CNQX plus a neurokinin-1 (NK-1) antagonist produced stronger inhibition, while co-application of CNQX, NK-1, and GRP receptor (GRPR) antagonists completely inhibited firing. Nociceptive-specific and wide dynamic range-type neurons exhibited differential suppression by CNQX plus either the GRPR or NK-1 antagonist, respectively. Neuronal responses elicited by i.d. histamine were abolished by CNQX alone. In behavioral studies, individual intrathecal administration of a GRPR, NK-1, or AMPA antagonist each significantly attenuated chloroquine-evoked scratching behavior. Co-administration of the NK-1 and AMPA antagonists was more effective, and administration of all 3 antagonists abolished scratching. Intrathecal CNQX alone prevented histamine-evoked scratching behavior. We additionally employed a double-label strategy to investigate molecular markers of pruritogen-sensitive dorsal root ganglion (DRG) cells. DRG cells responsive to histamine and/or chloroquine, identified by calcium imaging, were then processed for co-expression of SP, GRP, or vesicular glutamate transporter type 2 (VGLUT2) immunofluorescence. Subpopulations of chloroquine- and/or histamine-sensitive DRG cells were immunopositive for SP and/or GRP, with >80% immunopositive for VGLUT2. These results indicate that SP, GRP, and glutamate each partially contribute to histamine-independent itch. Histamine-evoked itch is mediated primarily by glutamate, with GRP playing a lesser role. Co-application of NK-1, GRP, and AMPA receptor antagonists may prove beneficial in treating chronic itch.
- Published
- 2014
66. A convenient and efficient total solid-phase synthesis of DOTA-functionalized tumor-targeting peptides for PET imaging of cancer
- Author
-
Subhani M. Okarvi and Ibrahim AlJammaz
- Subjects
DOTA ,cyclen ,Bombesin ,Solid-phase peptide synthesis ,Biodistribution ,Tumor imaging ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Introduction An efficient and cost-effective synthesis of the metal chelating agents that couple to tumor-targeting peptides is required to enhance the process of preclinical research toward the clinical translation of molecular imaging agents. DOTA is one of the most widely used macrocyclic ligands for the development of new metal-based imaging and therapeutic agents owing to its ability to form stable and inert complexes under physiological conditions. Although solid-phase synthesis compatible DOTA-tris-(t-Bu ester) is a commercial product, it is expensive and contain chemical impurities. There is a need to explore new and cost-effective methods for the preparation of metal chelating agents, i.e., DOTA, directly on solid support to facilitate rapid, cost-effective, and high purity preparation of DOTA-linked peptides for imaging and therapy. In the present study, we describe a facile synthetic strategy of DOTA preparation and its linkage to peptides directly on solid-phase support. Methods Bombesin (BN) peptides were functionalized with DOTA chelator prepared from cyclen precursor on solid-phase and from commercial DOTA-tris and radiolabeled with 68Ga. In vitro BN/GRP receptor binding affinities of the corresponding radiolabeled peptides were determined by saturation binding assays on human breast MDA-MB-231, MCF7, T47D, and PC3 prostate cancer cells. Pharmacokinetics were studied in Balb/c mice and in vivo tumor targeting in MDA-MB-231 tumor-bearing nude mice. Results DOTA was prepared successfully from cyclen on solid-phase support, linked specifically to BN peptides and resultant DOTA-coupled peptides were radiolabeled efficiently with 68Ga. The binding affinities of all the six BN peptides were comparable and in the low nanomolar range. All 68Ga-labeled peptides showed high metabolic stability in plasma. These radiopeptides exhibited rapid pharmacokinetics in Balb/c mice with excretion mainly through the urinary system. In nude mice, MDA-MB-231 tumor uptake profiles were slightly different; the BN peptide with Ahx spacer and linked to DOTA through cyclen exhibited higher tumor uptake (2.32% ID/g at 1 h post-injection) than other radiolabeled BN peptides investigated in this study. The same leading BN peptide also displayed favorable pharmacokinetic profile in Balb/c mice. The PET images clearly visualized the MDA-MB-231 tumor. Conclusions DOTA prepared from cyclen on solid-phase support showed comparable potency and efficiency to DOTA-tris in both in vitro and in vivo evaluation. The synthetic methodology described here allows versatile, site-specific introduction of DOTA into peptides to facilitate the development of DOTA-linked molecular imaging and therapy agents for clinical translation.
- Published
- 2019
- Full Text
- View/download PDF
67. 68Ga-radiolabeled bombesin-conjugated to trimethyl chitosan-coated superparamagnetic nanoparticles for molecular imaging: preparation, characterization and biological evaluation
- Author
-
Hajiramezanali M, Atyabi F, Mosayebnia M, Akhlaghi M, Geramifar P, Jalilian AR, Mazidi SM, Yousefnia H, Shahhosseini S, and Beiki D
- Subjects
Superparamagnetic iron oxide nanoparticles ,Trimethyl chitosan ,Bombesin ,Gallium-68 ,PET/MR imaging ,Medicine (General) ,R5-920 - Abstract
Maliheh Hajiramezanali,1 Fatemeh Atyabi,2,3 Mona Mosayebnia,1 Mehdi Akhlaghi,4 Parham Geramifar,4 Amir Reza Jalilian,4 Seyed Mohammad Mazidi,5 Hassan Yousefnia,6 Soraya Shahhosseini,7 Davood Beiki4 1Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; 2Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; 3Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; 4Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran; 5Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran; 6Material and Nuclear Fuel Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran; 7Department of Radiopharmacy and Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran Introduction: Nowadays, nanoparticles (NPs) have attracted much attention in biomedical imaging due to their unique magnetic and optical characteristics. Superparamagnetic iron oxide nanoparticles (SPIONs) are the prosperous group of NPs with the capability to apply as magnetic resonance imaging (MRI) contrast agents. Radiolabeling of targeted SPIONs with positron emitters can develop dual positron emission tomography (PET)/MRI agents to achieve better diagnosis of clinical conditions.Methods: In this work, N,N,N-trimethyl chitosan (TMC)-coated magnetic nanoparticles (MNPs) conjugated to S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (DOTA) as a radioisotope chelator and bombesin (BN) as a targeting peptide (DOTA–BN–TMC–MNPs) were prepared and validated using fourier transform infrared (FTIR) spectroscopy, transmission electron microscopy (TEM), thermogravimetric analysis (TGA), vibrating sample magnetometer (VSM), and powder X-ray diffraction (PXRD) tests. Final NPs were radiolabeled with gallium-68 (68Ga) and evaluated in vitro and in vivo as a potential PET/MRI probe for breast cancer (BC) detection.Results: The DOTA–BN–TMC–MNPs with a particle size between 20 and 30 nm were efficiently labeled with 68Ga (radiochemical purity higher than 98% using thin layer chromatography (TLC)). The radiolabeled NPs showed insignificant toxicity (>74% cell viability) and high affinity (IC50=8.79 µg/mL) for the gastrin-releasing peptide (GRP)-avid BC T-47D cells using competitive binding assay against 99mTc–hydrazinonicotinamide (HYNIC)–gamma-aminobutyric acid (GABA)–BN (7–14). PET and MRI showed visible uptake of NPs by T-47D tumors in xenograft mouse models.Conclusion: 68Ga–DOTA–BN–TMC–MNPs could be a potential diagnostic probe to detect BC using PET/MRI technique. Keywords: superparamagnetic iron oxide nanoparticles, trimethyl chitosan, bombesin, gallium-68, PET/MRI
- Published
- 2019
68. HYNIC and DOMA conjugated radiolabeled bombesin analogs as receptor-targeted probes for scintigraphic detection of breast tumor
- Author
-
Kakali De, Dibyanti Mukherjee, Samarendu Sinha, and Shantanu Ganguly
- Subjects
Bombesin ,Binding affinity ,GRP receptor ,Scintigraphy image ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Background Among the many peptide receptor systems, gastrin-releasing-peptide (GRP) receptors, the mammalian equivalent of bombesin (BN) receptors, are potential targets for diagnosis and therapy of breast tumors due to their overexpression in various frequently occurring human cancers. The aim of this study was to synthesize and comparative evaluation of 99mTc-labeled new BN peptide analogs. Four new BN analogs, HYNIC-Asp[PheNle]BN(7-14)NH2, BN1; HYNIC-Pro-Asp[TyrMet]BN(7-14)NH2, BN2; HYNIC-Asp-Asn[Lys-CHAla-Nle]BN(7-14)NH2, BN3; and DOMA-GABA[Pro-Tyr-Nle]BN(7-14)NH2, BN4 were synthesized and biologically evaluated for targeted imaging of GRP receptor-positive breast-tumors. Methods Solid-phase synthesis using Fmoc-chemistry was adopted for the synthesis of peptides. BN1–BN4 analogs were better over the standard Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 (BNS). Lipophilicity, serum stability, internalization, and binding affinity studies were carried out using 99mTc-labeled analogs. Biodistribution and imaging analyses were performed on MDA-MB-231 cell-induced tumor-bearing mice. BN-analogs induced angiogenesis; tumor formation and GRP-receptor-expression were confirmed by histology and immunohistochemistry analyses of tumor sections and important tissue sections. Results All the analogs displayed ≥ 97% purity after the HPLC purification. BN-peptide-conjugates exhibited high serum stability and significant binding affinity to GRP-positive tumor; rapid internalization/externalization in/from MDA-MB-231 cells were noticed for the BN analogs. BN4 and BN3 exhibited higher binding affinity, stability than BN1 and BN2. Highly specific in vivo uptakes to the tumor were clearly visualized by scintigraphy; rapid excretion from non-target tissues via kidneys suggests a higher tumor-to-background ratio. BN4, among all the analogs, stimulates the expression of angiogenic markers to a maximum. Conclusion Considering its most improved pharmacological characteristics, BN4 is thus considered as most promising probes for early non-invasive diagnosis of GRP receptor-positive breast tumors.
- Published
- 2019
- Full Text
- View/download PDF
69. 64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial
- Author
-
Keith Wong, Gemma Sheehan-Dare, Andrew Nguyen, Bao Ho, Victor Liu, Jonathan Lee, Lauren Brown, Rachel Dear, Lyn Chan, Shikha Sharma, Alessandra Malaroda, Isabelle Smith, Elgene Lim, and Louise Emmett
- Subjects
breast cancer ,bombesin ,staging ,PET ,copper 64 ,SAR-BBN ,Medicine ,Pharmacy and materia medica ,RS1-441 - Abstract
Breast cancers are most frequently oestrogen receptor (ER) and progesterone receptor (PR) positive and [18F]Fluorodeoxyglucose PET-CT (FDG) has lower sensitivity for these subtypes. The gastrin-releasing peptide receptor (GRPR) is overexpressed in ER+/PR+ breast cancers. This study assessed the safety and potential of [64Cu]Cu-Sarcophagine (SAR)-Bombesin PET/CT (BBN) in re-staging metastatic ER+/PR+/human epidermal growth-factor-2-negative (HER2-) breast cancer. Seven patients with metastatic ER+/PR+/HER2- breast cancer undergoing staging underwent [64Cu]Cu-SAR-BBN PET-CT. Bloods, vital signs and electrocardiogram, blood tracer-clearance and dosimetry were undertaken. GRPR status was assessed in available metastatic biopsy samples. Staging with conventional imaging ([18F]FDG, bone scan and diagnostic CT) was within 3 weeks of [64Cu]Cu-SAR-BBN PET/CT. PET scans were assessed visually and quantitatively. Seven patients underwent imaging. One of the seven had de-novo metastatic breast cancer and six of the seven recurrent metastatic disease. Two of the seven had lobular subtype. No adverse events were reported. All seven patients were positive on conventional imaging (six of seven on FDG). [64Cu]Cu-SAR-BBN imaging was positive in five of the seven. Both [64Cu]Cu-SAR-BBN-negative patients had disease identified on [18F]FDG. One patient was [64Cu]Cu-SAR-BBN positive/[18F]FDG negative. Four of seven patients were [64Cu]Cu-SAR-BBN positive/[18F]FDG positive. In these four, mean SUVmax was higher for [64Cu]Cu-SAR-BBN than [18F]FDG (SUVmax 15 vs. 12). In the classical lobular subtype (two of seven), [64Cu]Cu-SAR-BBN was more avid compared to [18F]FDG (SUVmax 20 vs. 11, and 20 vs. 64Cu]Cu-SAR-BBN to be 1.9 mSv. [64Cu]Cu-SAR-BBN PET/CT appears safe and may have diagnostic value in metastatic ER+/PR+/HER2- breast cancer, particularly the lobular subtype. Further evaluation is warranted.
- Published
- 2022
- Full Text
- View/download PDF
70. First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68Ga-NODAGA-MJ9
- Author
-
Silvano Gnesin, Francesco Cicone, Periklis Mitsakis, Axel Van der Gucht, Sébastien Baechler, Raymond Miralbell, Valentina Garibotto, Thomas Zilli, and John O. Prior
- Subjects
Gastrin-releasing peptide receptor ,Bombesin ,Dosimetry ,PET/CT ,68Ga-NODAGA-MJ9 ,OLINDA/EXM ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Background Gastrin-releasing peptide receptor antagonists have promise in theranostics of several highly incident tumours, including prostate and breast. This study presents the first human dosimetry of 68Ga-NODAGA-MJ9 in the first five consecutive patients with recurrent prostate cancer included in a dual-tracer positron emission tomography (PET) protocol. Five male patients with biochemical relapse of prostate adenocarcinoma underwent four whole-body time-of-flight PET/CT scans within 2 h after tracer injection. To be used as input in OLINDA/EXM 2.0, time-integrated activity coefficients were derived from manually drawn regions of interest over the following body regions: brain, thyroid, lungs, heart, liver, gallbladder, spleen, stomach, kidneys, adrenals, red marrow, pancreas, intestines, urinary bladder and whole body. Organ absorbed doses and effective dose (ED) were calculated with OLINDA/EXM 2.0 using the NURBS voxelized phantoms adjusted to the ICRP-89 organ masses and ICRP103 tissue-weighting factors. Additional absorbed dose estimations were performed with OLINDA/EXM 1.1 to be comparable with similar previous publications. Results The body regions receiving the highest absorbed doses were the pancreas, the urinary bladder wall, the small intestine and the kidneys (260, 69.8, 38.8 and 34.8 μGy/MBq respectively). The ED considering a 30-min urinary voiding cycle was 17.6 μSv/MBq in male patients. The increment of voiding time interval produced a significant increase of absorbed doses in bladder, prostate and testes, as well as an increase of ED. ED also increased if calculated with OLINDA/EXM 1.1. These results have been discussed in view of similar publications on bombesin analogues or on other commonly used theranostic peptides. Conclusions The pancreas is the most irradiated organ after the injection of 68Ga-NODAGA-MJ9, followed by the urinary bladder wall, the small intestine and the kidneys. ED is in the same range of other common 68Ga-labelled peptides. Differences with similarly published studies on bombesin analogues exist, and are mainly dependent on the methodology used for absorbed dose calculations. Trial registration Clinicaltrial.Gov identifier: NCT02111954, posted on 11/042014.
- Published
- 2018
- Full Text
- View/download PDF
71. Molecular Recognition of Itching Neuropeptides by Bombesin Receptors
- Subjects
Gastrin ,Protein binding ,Bombesin ,Pruritus ,Physical fitness ,Health - Abstract
2022 OCT 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]
- Published
- 2022
72. Bombesin-Tethered Reactive Oxygen Species (ROS)-Responsive Nanoparticles for Monomethyl Auristatin F (MMAF) Delivery.
- Author
-
Jihoon Kim, Jee Seon Kim, Kyung Hyun Min, Young-Hwa Kim, and Xiaoyuan Chen
- Subjects
- *
REACTIVE oxygen species , *DRUG delivery systems , *PEPTIDE receptors , *CELL receptors , *ANTIBODY-drug conjugates - Abstract
Dolastatin derivatives, represented by monomethylauristatin E (MMAE), have been translated in clinic with a form of antibody–drug conjugate; however, their potential in nanoparticle systems has not been well established due to the potential risk of immature release of extremely high cytotoxic dolastatin drugs during blood circulation. Herein, we rationally propose monomethylauristatin F (MMAF), a dolastatin-derived, loaded nanoparticle system composed of bombesin (BBN)-tethered ROS-responsive micelle system (BBN-PEG-PPADT) to achieve efficient anticancer therapy with targeted and efficient delivery of MMAF. The developed MMAF-loaded BBN-PEGPPADT micelles (MMAF@BBN-PEG-PPADT) exhibited improved cellular uptake via interactions between BBN and gastrin-releasing peptide receptors on the cancer cells and the intracellular burst release of MMAF, owing to the ROS-responsive disruption, which allowed the efficient anticancer effects of MMAF in vitro. This study suggests the potential of nanoparticle systems in the delivery of dolastatin drugs. Dolastatin derivatives, represented by monomethylauristatin E (MMAE), have been translated in clinic with a form of antibody–drug conjugate; however, their potential in nanoparticle systems has not been well established due to the potential risk of immature release of extremely high cytotoxic dolastatin drugs during blood circulation. Herein, we rationally propose monomethylauristatin F (MMAF), a dolastatin-derived, loaded nanoparticle system composed of bombesin (BBN)-tethered ROS-responsive micelle system (BBN-PEG-PPADT) to achieve efficient anticancer therapy with targeted and efficient delivery of MMAF. The developed MMAF-loaded BBN-PEGPPADT micelles (MMAF@BBN-PEG-PPADT) exhibited improved cellular uptake via interactions between BBN and gastrin-releasing peptide receptors on the cancer cells and the intracellular burst release of MMAF, owing to the ROS-responsive disruption, which allowed the efficient anticancer effects of MMAF in vitro. This study suggests the potential of nanoparticle systems in the delivery of dolastatin drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
73. First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial
- Subjects
Prostate cancer ,Bombesin ,General interest ,News, opinion and commentary - Abstract
SYDNEY: Clarity Pharmaceuticals has issued the following news release: Clarity Pharmaceuticals (ASX: CU6) ('Clarity'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for [...]
- Published
- 2023
74. First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial
- Subjects
Prostate cancer ,Metastasis ,Bombesin ,Business ,News, opinion and commentary - Abstract
SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ('Clarity'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults [...]
- Published
- 2023
75. Fractal and multifractal characterization of in vitro respiratory recordings of the pre-Bötzinger complex
- Author
-
Ulises Paredes-Hernández, Patricia Pliego-Pastrana, Enrique Vázquez-Mendoza, Consuelo Morgado-Valle, Luis Beltran-Parrazal, Arturo Criollo-Perez, and Erika Elizabeth Rodriguez-Torres
- Subjects
Fractal ,Multifractal ,Respiratory rhythm ,Pre-Bötzinger complex ,Bombesin ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
The pre-Bötzinger complex is a neural network located in the ventrolateral brainstem that generates the respiratory rhythm. Under normoxic conditions, this area shows two inspiratory burst patterns, sigh and non-sigh. Several studies have shown that in vitro application of peptides, such as bombesin, stimulates the respiratory rate and increases the appearance of sighs. However, it is difficult to distinguish between sighs and non-sighs waveforms, which makes it difficult to study their properties under experimental conditions. The fractal and multifractal analysis have proven to be valuable tools for studying physiological time series, thus in this study, we applied this methodology to characterize sighs and non-sighs. Our results regarding fractality, shown that the sighs and non-sighs have similar Hurst exponents and that the application of bombesin only decreased the Hurst exponent of non-sighs. On the other hand, our results on multifractality parameters scaling exponent (τ(q)) and generalized Hurst exponent (H(q)) shown that both sighs and non-sighs were multifractal and this remained even after the application of bombesin. Further analysis showed that sighs and non-sighs had different H(q) values, which changed after the bombesin application. To quantitatively analyzed the multifractal spectrum, we calculated the area of the spectrum (Iα), which was similar between sighs and non-sighs and the application of bombesin did not change this. Altogether, these results show that the analysis of fractal and multifractal parameters allows to characterize and find statistical differences of sighs and non-sighs within and between different experimental conditions. Statement of Significance: The characterization of the respiratory recordings is very difficult and time consuming when is done manually by a researcher. An automated software that can aid this can be very useful. Furthermore, this gives some parameters that can help to statistically differentiate between sighs and non sighs. One interesting finding was that multifractality show differences in the same condition between sighs and non sighs. Also, we found that the neuropeptide bombesin increases the number of sighs without changing the intrinsic structure of the respiration system. This is important to avoid the collapse of the lungs that can be incorporated in mechanical ventilators. We hope that you will find our paper suitable for publication in Brain Multiphysics and will look forward to receiving your response.
- Published
- 2021
- Full Text
- View/download PDF
76. Recent updates and developments in PET imaging of prostate cancer.
- Author
-
Rowe, Steven P., Johnson, Geoffrey B., Pomper, Martin G., Gorin, Michael A., and Behr, Spencer C.
- Subjects
- *
PROSTATE-specific membrane antigen , *PROSTATE cancer , *PEPTIDE receptors , *RADIOACTIVE tracers , *POSITRON emission tomography , *REGULATORY approval - Abstract
A number of positron emission tomography (PET) radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer. These radiotracers include the bone-seeking agent Na18F as well as more tumor-specific compounds such as 11C-choline and 18F-fluciclovine. In this review, we will discuss the advantages and disadvantages of these PET radiotracers for the imaging of men with prostate cancer across a range of clinical contexts. We will also touch upon radiotracers in late clinical development that have not gained regulatory approval, including those targeted against prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
77. <bold>In Vitro</bold> Evaluation and Biodistribution Studies of HPMA Copolymers Targeting the Gastrin Releasing Peptide Receptor in Prostate Cancer.
- Author
-
Alshehri, Sameer, Fan, Wei, Zhang, Wenting, and Garrison, Jered C.
- Abstract
Purpose: The development of diagnostic and therapeutic agents utilizing small peptides (e.g., bombesin (BBN)) to target the overexpression of the gastrin-releasing peptide receptor (GRPR) in cancers has been widely investigated. Herein, we examine the capabilities of BBN-modified HPMA copolymers to target the GRPR. Methods: Four positive, four negative, and two zwitterionic BBN HPMA copolymer conjugates of varying peptide content and charge were synthesized. In vitro and in vivo studies were conducted in a GRPR-overexpressing prostate cancer cell line (PC-3) and a normal CF-1 mouse model, respectively. Results: Cellular uptake of the conjugates were found to be charge and BBN density dependent. The positively-charged conjugates illustrated a direct relationship between the extent of cellular internalization, ranging from 0.7 to 20%, and BBN-incorporation density. The negative and zwitterionic conjugates showed low PC-3 uptake values. Blocking studies confirmed the GRPR-targeting effect of the positively-charged constructs. In vivo studies of the positively-charged copolymers resulted in rapid blood clearance by the mononuclear phagocyte system (MPS)-associated tissues (e.g., liver and spleen). Conclusion: Positively-charged BBN-HPMA copolymer conjugates demonstrated good GRPR-targeting and internalization in vitro. However, the impact of peptide density and charge on in vivo MPS recognition are parameters that must be optimized in future agent development. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
78. Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study.
- Author
-
Egloff, Ann Marie, Gaither Davis, Autumn, Shuai, Yongli, Land, Stephanie, Pilewski, Joseph M, Luketich, James D, Landreneau, Rodney, Miller, York E, Grandis, Jennifer R, and Siegfried, Jill M
- Subjects
Lung ,Bronchi ,Humans ,Adenocarcinoma ,Carcinoma ,Non-Small-Cell Lung ,Carcinoma ,Squamous Cell ,Lung Neoplasms ,Receptors ,Bombesin ,Risk ,Case-Control Studies ,Smoking ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Female ,Male ,Small Cell Lung Carcinoma ,Adenocarcinoma of Lung ,Gastrin-releasing peptide receptor ,lung cancer risk ,case-control study ,surrogate tissue ,Carcinoma ,Non-Small-Cell Lung ,Squamous Cell ,Receptors ,Bombesin ,and over ,Respiratory System ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences - Abstract
BackgroundNormal bronchial tissue expression of GRPR, which encodes the gastrin-releasing peptide receptor, has been previously reported by us to be associated with lung cancer risk in 78 subjects, especially in females. We sought to define the contribution of GRPR expression in bronchial epithelia to lung cancer risk in a larger case-control study where adjustments could be made for tobacco exposure and sex.MethodsWe evaluated GRPR mRNA levels in histologically normal bronchial epithelial cells from 224 lung cancer patients and 107 surgical cancer-free controls. Associations with lung cancer were tested using logistic regression models.ResultsBronchial GRPR expression was significantly associated with lung cancer (OR = 4.76; 95% CI = 2.32-9.77) in a multivariable logistic regression (MLR) model adjusted for age, sex, smoking status and pulmonary function. MLR analysis stratified by smoking status indicated that ORs were higher in never and former smokers (OR = 7.74; 95% CI = 2.96-20.25) compared to active smokers (OR = 1.69; 95% CI = 0.46-6.33). GRPR expression did not differ by subject sex, and lung cancer risk associated with GRPR expression was not modified by sex.ConclusionsGRPR expression in non-cancerous bronchial epithelium was significantly associated with the presence of lung cancer in never and former smokers. The association in never and former smokers was found in males and females. Association with lung cancer did not differ by sex in any smoking group.
- Published
- 2012
79. CCK‐1 and CCK‐2 receptor agonism do not stimulate GLP‐1 and neurotensin secretion in the isolated perfused rat small intestine or GLP‐1 and PYY secretion in the rat colon
- Author
-
Ida M. Modvig, Charlotte B. Christiansen, Jens F. Rehfeld, Jens J. Holst, and Simon Veedfald
- Subjects
bombesin ,CCK ,cholecystokinin ,colon ,ex vivo ,gastrin ,Physiology ,QP1-981 - Abstract
Abstract Gastrin and cholecystokinin (CCK) are hormones released from endocrine cells in the antral stomach (gastrin), the duodenum, and the jejunum (CCK). Recent reports, based on secretion experiments in an enteroendocrine cell line (NCI‐H716) and gastrin receptor expression in proglucagon‐expressing cells from the rat colon, suggested that gastrin could be a regulator of glucagon‐like peptide‐1 (GLP‐1) secretion. To investigate these findings, we studied the acute effects of CCK‐8 (a CCK1/CCK2 (gastrin) receptor agonist) and gastrin‐17 (a CCK2(gastrin) receptor agonist) in robust ex vivo models: the isolated perfused rat small intestine and the isolated perfused rat colon. Small intestines from Wistar rats (n = 6), were perfused intraarterially over 80 min. During the perfusion, CCK (1 nmol/L) and gastrin (1 nmol/L) were infused over 10‐min periods separated by washout/baseline periods. Colons from Wistar rats (n = 6) were perfused intraarterially over 100 min. During the perfusion, CCK (1 nmol/L), vasoactive intestinal peptide (VIP) (10 nmol/L), and glucose‐dependent insulinotropic polypeptide (GIP) (1 nmol/L) were infused over 10‐min periods separated by washout/baseline periods. In the perfused rat small intestines neither CCK nor gastrin stimulated the release of GLP‐1 or neurotensin. In the perfused rat colon, neither CCK or VIP stimulated GLP‐1 or peptide YY (PYY) release, but GIP stimulated both GLP‐1 and PYY release. In both sets of experiments, bombesin, a gastrin‐releasing peptide analog, served as a positive control. Our findings do not support the suggestion that gastrin or CCK participate in the acute regulation of intestinal GLP‐1 secretion, but that GIP may play a role in the regulation of hormone secretion from the colon.
- Published
- 2020
- Full Text
- View/download PDF
80. Вікові особливості впливу бомбезину на жовчосекреторну функцію печінки
- Author
-
Мороз, О. Ф., Весельський, С. П., and Лященко, Т. П.
- Subjects
- *
THIN layer chromatography , *ANIMAL young , *BILE acids , *BILE salts , *BODY weight - Abstract
Hepatic bile formation under bombesin action (1 μg/100 g body weight, intraportally) was examined in acute experiments on 30 male rats of three age categories: juvenile (body weight 130-175 g), adult (200-250 g) and elder (more than 300 g). Changes in the bile flow rate were recorded and the amount of various bile acids (BA) was detected using thin layer chromatography/densitometry. Bombesin caused the increase of the bile flow rate in juvenile and adult rats without any effect on it in old animals. The concentration of free bile acids increased in juvenile and adult rats and decreased in old animals. This peptide stimulated secretion of taurocholic and glicocholic acids in adult and aged rats but had no effect on the secretion of tauroconjugated dihydroxycholates. Secretion of dihydroxy bile salts conjugated with glycine was more potently enhanced by bombesin in adult rats but in the elder group this parameter dropped below the control. Bombesin had a lower effect on the BA secretion in aged rats but its influence on the juvenile animals was bidirectional. In this group the peptide stimulates free bile salts formation and, without affecting de novo synthesis, inhibits BA conjugation with amino acids in aged group. Bombesin activated classic pathway of BA biosynthesis in juvenile rats and suppressed it in aged animals. The data obtained demonstrate that different effect of bombesin on bile acids content in rats of different age could change biliary lipid-solubilizing capacity under age related damage of the gut with impairment of normal bombesin release. [ABSTRACT FROM AUTHOR]
- Published
- 2020
81. Nose-to-brain drug delivery system with ligand/cell-penetrating peptide-modified polymeric nano-micelles for intracerebral gliomas.
- Author
-
Kanazawa, Takanori, Taki, Hiroyuki, and Okada, Hiroaki
- Subjects
- *
DRUG delivery systems , *BRAIN tumors , *TREATMENT effectiveness , *ETHYLENE glycol , *MICELLES - Abstract
• Bombesin modified PEG-PCL-Tat micelles formed by solvent dilution method. • Bombesin modification exhibited selectively targeting to GRPR-positive glioma. • Bombesin modified micelles selectively migrated glioma by intranasal delivery. • Drug-loaded bombesin-micelles superior treated gliomas by intranasal delivery. We previously developed a nose-to-brain delivery system using poly(ethylene glycol)-polycaprolactone block polymeric micelles modified by a cell-penetrating peptide, Tat (PEG-PCL-Tat). This system showed excellent delivery of the anti-cancer drug camptothecin to the brain and improved therapeutic efficacy in a brain tumor model. However, improvements are necessary to selectively deliver drugs to tumor sites once they enter the brain, and avoid toxic side effects to normal brain tissue. In this study, to develop tumor-selective novel polymeric micelles, mixed micelles consisting of Tat-conjugated polymer micelles and stearoyl-modified bombesin (Bom/PEG-PCL-Tat) were designed. The GRPR selectivity, cellular uptake, and cytotoxicity in C6 glioma cells as well as the intracerebral drug distribution and therapeutic efficacy of Bom/PEG-PCL-Tat mixed micelles after intranasal administration in C6 glioma orthotropic grafted rats were evaluated. Selective cellular uptake and marked cytotoxic effects against GRPR-expressing C6 glioma cells were observed, as well as C6 tumor tissue-specific accumulation in vivo. Rats treated with camptothecin subsequent to a brain tumor graft survived longer when the drug was delivered by Bom/PEG-PCL-Tat mixed micelles than by PEG-PCL-Tat micelles. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
82. Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer.
- Author
-
Fassbender, Thomas Franz, Schiller, Florian, Zamboglou, Constantinos, Drendel, Vanessa, Kiefer, Selina, Jilg, Cordula A., Grosu, Anca-Ligia, and Mix, Michael
- Subjects
- *
FLUORODEOXYGLUCOSE F18 , *CANCER diagnosis , *PEPTIDE receptors , *POSITRON emission tomography computed tomography , *PROSTATE-specific membrane antigen , *PROSTATE cancer - Abstract
Background: Focal therapies or focally escalated therapies of primary prostate cancer are becoming more and more important. This increases the need to identify the exact extension of the intraprostatic tumor and possible dominant intraprostatic lesions by imaging techniques. While the prostate-specific membrane antigen (PSMA) is already a well-established target for imaging of prostate cancer cells, the gastrin-releasing peptide receptor (GRPR) seems to provide interesting additional information. Histopathology was used to examine the extent to which the single and combined image information of PET scans targeting GRPR and PSMA might lead to better tumor delineation. Methods: Eight patients with histologically proven primary prostate cancer underwent two positron emission tomography with computer tomography scans, [68Ga]Ga-RM2-PET/CT (RM2-PET) and [68Ga]Ga-PSMA-11-PET/CT (PSMA-PET), prior to radical prostatectomy. RM2-PET data were correlated voxel-wise to a voxel-based model of the histopathologic tumor volume information. The results were compared to, correlated to, and combined with the correlation of PSMA-PET data analyzed analogously. Results: In 4/8 patients, RM2-PET showed a higher signal in histologically proven tumor regions compared to PSMA. There were also tumor regions where PSMA-PET showed a higher signal than GRPR in 4/8 patients. A voxel-wise correlation of RM2-PET against histopathology yielded similar results compared to the correlation of PSMA-PET against histopathology, while PSMA-PET is the slightly better performing imaging technique. The combined information of both tracers yielded the best overall result, although this effect was not statistically significant compared to RM2-PET alone. Conclusions: Qualitative and quantitative findings in this preliminary study with 8 patients indicate that RM2-PET and PSMA-PET partially show not only the same, but also distinct regions of prostate cancer. Patients with pPCa might profit from information given by tracers targeting GRPR and PSMA simultaneously, in terms of a better delineation of the gross tumor volume. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
83. Comparison of biological properties of [177Lu]Lu‐ProBOMB1 and [177Lu]Lu‐NeoBOMB1 for GRPR targeting.
- Author
-
Rousseau, Etienne, Lau, Joseph, Zhang, Zhengxing, Zhang, Chengcheng, Kwon, Daniel, Uribe, Carlos F., Kuo, Hsiou‐Ting, Zeisler, Jutta, Bratanovic, Ivica, Lin, Kuo‐Shyan, and Bénard, François
- Subjects
- *
RADIOCHEMICAL purification , *PEPTIDE receptors , *LUTETIUM compounds , *PROSTATE cancer , *MOLARS , *RADIOPHARMACEUTICALS - Abstract
The gastrin‐releasing peptide receptor (GRPR) is overexpressed in prostate cancer and other solid malignancies. Following up on our work on [68Ga]Ga‐ProBOMB1 that had better imaging characteristics than [68Ga]Ga‐NeoBOMB1, we investigated the effects of substituting 68Ga for 177Lu to determine if the resulting radiopharmaceuticals could be used with a therapeutic aim. We radiolabeled the bombesin antagonist ProBOMB1 (DOTA‐pABzA‐DIG‐D‐Phe‐Gln‐Trp‐Ala‐Val‐Gly‐His‐Leu‐ψ‐Pro‐NH2) with lutetium‐177 and compared it with [177Lu]Lu‐NeoBOMB1 (obtained in 54.2 ± 16.5% isolated radiochemical yield with >96% radiochemical purity and 440.8 ± 165.1 GBq/μmol molar activity) for GRPR targeting. Lu‐NeoBOMB1 had better binding affinity for GRPR than Lu‐ProBOMB1 (Ki values: 2.26 ± 0.24 and 30.2 ± 3.23nM). [177Lu]Lu‐ProBOMB1 was obtained in 53.7 ± 5.4% decay‐corrected radiochemical yield with 444.2 ± 193.2 GBq/μmol molar activity and >95% radiochemical purity. In PC‐3 prostate cancer xenograft mice, tumor uptake of [177Lu]Lu‐ProBOMB1 was 3.38 ± 1.00, 1.32 ± 0.24, and 0.31 ± 0.04%ID/g at 1, 4, and 24 hours pi. However, the uptake in tumor was lower than [177Lu]Lu‐NeoBOMB1 at all time points. [177Lu]Lu‐ProBOMB1 was inferior to [177Lu]Lu‐NeoBOMB1, which had better therapeutic index for the organs receiving the highest doses. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
84. Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer.
- Author
-
Pagoto, Amerigo, Garello, Francesca, Marini, Giada Maria, Tripepi, Martina, Arena, Francesca, Bardini, Paola, Stefania, Rachele, Lanzardo, Stefania, Valbusa, Giovanni, Porpiglia, Francesco, Manfredi, Matteo, Aime, Silvio, and Terreno, Enzo
- Subjects
- *
COMPUTER-assisted surgery , *PEPTIDE receptors , *PROSTATE surgery , *PROSTATE cancer , *ONCOLOGIC surgery - Abstract
Purpose: Prostate cancer (PCa), the most widespread male cancer in western countries, is generally eradicated by surgery, especially if localized. However, during surgical procedures, it is not always possible to identify malignant tissues by visual inspection. Among the possible consequences, there is the formation of positive surgical margins, often associated with recurrence. In this work, the gastrin-releasing peptide receptor (GRPR), overexpressed in the prostatic carcinoma and not in healthy tissues or in benign hyperplasia (BPH), is proposed as target molecule to design a novel near-infrared fluorescent (NIRF) probe for image-guided prostatectomy.Procedures: The NIRF dye Sulfo-Cy5.5 was conjugated to a Bombesin-like peptide (BBN), targeting GRPR. The final product, called BBN-Cy5.5, was characterized and tested in vitro on PC-3, DU145, and LnCAP cell lines, using unconjugated Sulfo-Cy5.5 as control. In vivo biodistribution studies were performed by optical imaging in PC-3 tumor-bearing and healthy mice. Finally, simulation of the surgical protocol was carried out.Results: BBN-Cy5.5 showed high water solubility and a good relative quantum yield. The ability of the probe to recognize the GRPR, highly expressed in PC-3 cells, was tested both in vitro and in vivo, where a significant tumor accumulation was achieved 24 h post-injection. Furthermore, a distinguishable fluorescent signal was visible in mice bearing PCa, when the surgery was simulated. By contrast, low signal was found in healthy or BPH-affected mice.Conclusions: This work proposes a new NIRF probe ideal to target GRPR, biomarker of PCa. The promising data obtained suggest that the dye could allow the real-time intraoperative visualization of prostate cancer. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
85. Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements.
- Author
-
Baratto, Lucia, Duan, Heying, Laudicella, Riccardo, Toriihara, Akira, Hatami, Negin, Ferri, Valentina, and Iagaru, Andrei
- Subjects
- *
GASTROINTESTINAL system , *PROSTATE cancer , *PEPTIDE receptors , *ADRENAL glands , *THORACIC aorta , *EXOCRINE glands , *RECTUM - Abstract
Aim: 68Ga-RM2 is a bombesin (BBN) analog that targets the gastrin releasing peptide receptors (GRPR) overexpressed in many cancer cells, including prostate cancer (PC). It has been reported to successfully detect primary and recurrent PC. Here, we describe the distribution and range of physiological uptake of 68Ga-RM2 in 95 patients with biochemically recurrent (BCR) PC. Materials and methods: Ninety-five participants had simultaneous PET/MRI for BCR PC and were prospectively enrolled in this study. Maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) were measured in 24 normal anatomical structures for each participant. Three readers evaluated the images independently. Uptake in various normal tissues was classified into 4 different categories: no significant uptake if SUVmean was less than SUVmean of the aortic arch (AA); mild if SUVmean was less or equal to 2.5, but higher than SUVmean of the AA; moderate if SUVmean was higher than 2.5, but less or equal to 5; intense if SUVmean was higher than 5. Results: The most intense uptake was observed in the urinary bladder, due to excretion of the radiotracer. No significant uptake was seen in the brain, salivary glands, lungs, myocardium, skeleton, muscles, and fat. Liver, spleen, and adrenal glands had mostly no significant uptake; the gastrointestinal tract had intense physiological uptake, with pancreas being the organ with the highest SUVmax measurements (average SUVmax 64.91). Mild and moderate uptake was measured in the esophagus (average SUVmax 3.99), while the stomach wall, duodenum, and rectum had mild uptake (average SUVmax 2.49, 3.42, and 3.58, respectively). Conclusions: 68Ga-RM2 has been mostly evaluated for PC detection, but it can be used for other tumors overexpressing GRPR such as breast cancer. This atlas of normal biodistribution and SUV measurements in healthy tissues will help physicians distinguish between physiological vs. pathological uptake, as well as potentially assist with planning future studies using GRPR targeting radiopharmaceuticals. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
86. Peptide receptors as cancer drug targets.
- Author
-
Moody, Terry W.
- Subjects
- *
DRUG receptors , *PEPTIDE receptors , *CELL receptors , *G protein coupled receptors , *SMALL cell lung cancer , *CYCLIC-AMP-dependent protein kinase , *NEUROPEPTIDES - Abstract
Neuropeptides function as neuromodulators in the brain, whereby they are released in a paracrine manner and activate G protein–coupled receptors (GPCRs) in adjacent cells. Because neuropeptides are made in, and secreted from, cancer cells, then bind to cell surface receptors, they function in an autocrine manner. Bombesin (BB)‐like peptides synthesized by neuroendocrine tumor small cell lung cancer (SCLC) bind to BB receptors (BBRs), causing phosphatidylinositol turnover and phosphorylation of extracellular signal–regulated kinase (ERK). Phosphorylated ERK enters the nucleus and alters gene expression of SCLC cells, stimulating growth. Vasoactive intestinal peptide (VIP) addition to SCLC cells increases their release rate of BB‐like peptides via activation of VIP receptors (VIPR), leading to activation of adenylyl cyclase and subsequent elevation of cAMP. Protein kinase A is then stimulated, leading to phosphorylation of cyclic AMP response element binding protein (CREB), which alters gene expression and stimulates proliferation. The growth of SCLC is inhibited by BBR and VIPR antagonists. This review will focus on how GPCRs for VIP and BB are molecular targets for early detection and treatment of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
87. Molecular Targets in Human Neuroendocrine Tumors
- Author
-
Sheikh, Ujalla, Muhammad, Jalil, Coppola, Domenico, Nasir, Aejaz, Nasir, Aejaz, editor, and Coppola, Domenico, editor
- Published
- 2016
- Full Text
- View/download PDF
88. Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers
- Published
- 2014
89. Clarity commences COMBAT theranostic prostate cancer trial in the US
- Subjects
Prostate cancer ,Bombesin ,General interest ,News, opinion and commentary - Abstract
SYDNEY: Clarity Pharmaceuticals has issued the following news release: Clarity Pharmaceuticals (ASX: CU6) ('Clarity'), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes [...]
- Published
- 2023
90. Clarity commences COMBAT theranostic prostate cancer trial in the US
- Subjects
Prostate cancer ,Metastasis ,Bombesin ,Business ,News, opinion and commentary - Abstract
SYDNEY, June 20, 2023 /PRNewswire/ --Clarity Pharmaceuticals (ASX: CU6) ('Clarity'), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults [...]
- Published
- 2023
91. Targeting Itch with Ligands Selective for κ Opioid Receptors
- Author
-
Cowan, Alan, Kehner, George B., Inan, Saadet, Rosenthal, Walter, Editor-in-chief, Barrett, James E., Series editor, Flockerzi, Veit, Series editor, Frohman, Michael A., Series editor, Geppetti, Pierangelo, Series editor, Hofmann, Franz B., Series editor, Michel, Martin C., Series editor, Moore, Philip, Series editor, Page, Clive P., Series editor, Thorburn, Andrew M., Series editor, Wang, KeWei, Series editor, Cowan, Alan, editor, and Yosipovitch, Gil, editor
- Published
- 2015
- Full Text
- View/download PDF
92. PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
- Published
- 2013
93. Investigators from University of Veracruzana Target Peptide Hormones (Modulation of Inspiratory Burst Duration and Frequency By Bombesin In Vitro)
- Subjects
Hormones ,Bombesin ,Biological sciences ,Health - Abstract
2023 OCT 31 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators publish new report on Peptide Proteins - Peptide Hormones. According to news originating [...]
- Published
- 2023
94. Data from Nuclear Science and Technology Research Institute Provide New Insights into Immunologic Receptors (68ga-labeled Nodaga-rgd-bbn Heterodimer Peptide As a Novel Radiotracer for Dual Integrin and Grpr-targeted Tumor Imaging)
- Subjects
Tumors ,Aspartate ,Integrins ,Immunity ,Bombesin ,Acetic acid ,Medical imaging equipment ,Diagnostic imaging ,Health ,Law - Abstract
2023 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Imaging Law Weekly -- New research on Membrane Proteins - Immunologic Receptors is the subject of a [...]
- Published
- 2023
95. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein–coupled receptors
- Author
-
Yan, Yibing, Shirakabe, Kyoko, and Werb, Zena
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,1.1 Normal biological development and functioning ,Underpinning research ,Generic health relevance ,Animals ,COS Cells ,Disintegrins ,Drosophila ,Drosophila Proteins ,Epidermal Growth Factor ,ErbB Receptors ,GTP-Binding Proteins ,Heparin-binding EGF-like Growth Factor ,Intercellular Signaling Peptides and Proteins ,Metalloendopeptidases ,Signal Transduction ,Transcriptional Activation ,signal crosstalk ,bombesin ,HB-EGF ,shedding ,tetraspanin ,Medical and Health Sciences ,Developmental Biology ,Biological sciences ,Biomedical and clinical sciences - Abstract
Communication between different signaling pathways enables cells to coordinate the responses to diverse environmental signals. Activation of the transmembrane growth factor precursors plays a critical role in this communication and often involves metalloprotease-mediated proteolysis. Stimulation of G protein-coupled receptors (GPCR) transactivates the EGF receptors (EGFRs), which occurs via a metalloprotease-dependent cleavage of heparin-binding EGF (HB-EGF). However, the metalloprotease mediating the transactivation remains elusive. We show that the integral membrane metalloprotease Kuzbanian (KUZ; ADAM10), which controls Notch signaling in Drosophila, stimulates GPCR transactivation of EGFR. Upon stimulation of the bombesin receptors, KUZ increases the docking and activation of adaptors Src homology 2 domain-containing protein and Gab1 on the EGFR, and activation of Ras and Erk. In contrast, transfection of a protease domain-deleted KUZ, or blocking endogenous KUZ by morpholino antisense oligonucleotides, suppresses the transactivation. The effect of KUZ on shedding of HB-EGF and consequent transactivation of the EGFR depends on its metalloprotease activity. GPCR activation enhances the association of KUZ and its substrate HB-EGF with tetraspanin CD9. Thus, KUZ regulates the relay between the GPCR and EGFR signaling pathways.
- Published
- 2002
96. Gastrin-releasing peptide receptor-targeted gadolinium oxide-based multifunctional nanoparticles for dual magnetic resonance/fluorescent molecular imaging of prostate cancer
- Author
-
Cui DT, Lu XD, Yan CG, Liu X, Hou MR, Xia Q, Xu YK, and Liu RY
- Subjects
Magnetic resonance imaging ,Gadolinium oxide ,Bombesin ,Gastrin-releasing peptide receptor ,Molecular imaging ,Medicine (General) ,R5-920 - Abstract
Danting Cui,1 Xiaodan Lu,1 Chenggong Yan,1 Xiang Liu,1 Meirong Hou,1 Qi Xia,2 Yikai Xu,1 Ruiyuan Liu2,3 1Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 2School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, People’s Republic of China; 3School of Biomedical Engineering, Southern Medical University, Guangzhou, People’s Republic of China Abstract: Bombesin (BBN), an analog of gastrin-releasing peptide (GRP), specifically binds to GRP receptors, which are overexpressed in human prostate cancer (PC). Here, we synthesized a BBN-modified gadolinium oxide (Gd2O3) nanoprobe containing fluorescein (Gd2O3-5(6)-carboxyfluorescein [FI]-polyethylene glycol [PEG]-BBN) for targeted magnetic resonance (MR)/optical dual-modality imaging of PC. The Gd2O3-FI-PEG-BBN nanoparticles exhibited a relatively uniform particle size with an average diameter of 52.3 nm and spherical morphology as depicted by transmission electron microscopy. The longitudinal relaxivity (r1) of Gd2O3-FI-PEG-BBN (r1 =4.23 mM–1s–1) is comparable to that of clinically used Magnevist (Gd-DTPA). Fluorescence microscopy and in vitro cellular MRI demonstrated GRP receptor-specific and enhanced cellular uptake of the Gd2O3-FI-PEG-BBN in PC-3 tumor cells. Moreover, Gd2O3-FI-PEG-BBN showed more remarkable contrast enhancement than the corresponding nontargeted Gd2O3-FI-PEG according to in vivo MRI and fluorescent imaging. Tumor immunohistochemical analysis further demonstrated improved accumulation of the targeted nanoprobe in tumors. BBN-conjugated Gd2O3 may be a promising nanoplatform for simultaneous GRP receptor-targeted molecular cancer diagnosis and antitumor drug delivery in future clinical applications. Keywords: magnetic resonance imaging, gadolinium oxide, bombesin, gastrin-releasing peptide receptor, molecular imaging
- Published
- 2017
97. Characterization of the expression of gastrin‐releasing peptide and its receptor in the trigeminal and spinal somatosensory systems of Japanese macaque monkeys: Insight into humans
- Author
-
Keiko Takanami, Takumi Oti, Yasuhisa Kobayashi, Koki Hasegawa, Takashi Ito, Naoaki Tsutsui, Yasumasa Ueda, Earl Carstens, Tatsuya Sakamoto, and Hirotaka Sakamoto
- Subjects
DNA, Complementary ,gastrin-releasing peptide receptor ,primates ,1.1 Normal biological development and functioning ,Medical Physiology ,Neurodegenerative ,Ligands ,gastrin-releasing peptide ,Macaca fuscata ,Underpinning research ,Complementary ,Receptors ,Animals ,Humans ,itch ,ligand derivative stain ,Neurology & Neurosurgery ,Pruritus ,General Neuroscience ,Neurosciences ,Sense Organs ,DNA ,macaque monkey ,Receptors, Bombesin ,Gastrin-Releasing Peptide ,trigeminal sensory system ,Bombesin ,Zoology ,Biotechnology - Abstract
Gastrin-releasing peptide (GRP) and its receptor (GRPR) have been identified as itch mediators in the spinal and trigeminal somatosensory systems in rodents. In primates, there are few reports of GRP/GRPR expression or function in the spinal sensory system and virtually nothing is known in the trigeminal system. The aim of the present study was to characterize GRP and GRPR in the trigeminal and spinal somatosensory system of Japanese macaque monkeys (Macaca fuscata). cDNA encoding GRP was isolated from the macaque dorsal root ganglion (DRG) and exhibited an amino acid sequence that was highly conserved among mammals and especially in primates. Immunohistochemical analysis demonstrated that GRP was expressed mainly in the small-sized trigeminal ganglion and DRG in adult macaque monkeys. Densely stained GRP-immunoreactive (ir) fibers were observed in superficial layers of the spinal trigeminal nucleus caudalis (Sp5C) and the spinal cord. In contrast, GRP-ir fibers were rarely observed in the principal sensory trigeminal nucleus and oral and interpolar divisions of the spinal trigeminal nucleus. cDNA cloning, in situ hybridization, and Western blot revealed substantial expression of GRPR mRNA and GRPR protein in the macaque spinal dorsal horn and Sp5C. Our Western ligand blot and ligand derivative stain for GRPR revealed that GRP directly bound in the macaque Sp5C and spinal dorsal horn as reported in rodents. Finally, GRP-ir fibers were also detected in the human spinal dorsal horn. The spinal and trigeminal itch neural circuits labeled with GRP and GRPR appear to function also in primates.
- Published
- 2022
98. Opioid/Dopamine Receptor Binding Studies, NMR and Molecular Dynamics Simulation of LENART01 Chimera, an Opioid-Bombesin-like Peptide.
- Author
-
Serafin P, Szeleszczuk Ł, Zhukov I, Szűcs E, Gombos D, Stefanucci A, Mollica A, Pisklak DM, and Kleczkowska P
- Subjects
- Dopamine, Molecular Dynamics Simulation, Molecular Docking Simulation, Receptors, Dopamine, Opioid Peptides, Magnetic Resonance Spectroscopy, Analgesics, Opioid pharmacology, Bombesin
- Abstract
The design and development of hybrid compounds as a new class of drug candidates remains an excellent opportunity to improve the pharmacological properties of drugs (including enzymatic stability, efficacy and pharmacokinetic and pharmacodynamic profiles). In addition, considering various complex diseases and/or disorders, the conjugate chemistry approach is highly acceptable and justified. Opioids have long been recognized as the most potent analgesics and serve as the basic pharmacophore for potent hybrid compounds that may be useful in pain management. However, a risk of tolerance and physical dependence exists. Since dopamine receptors have been implicated in the aforementioned adverse effects of opioids, the construction of a hybrid with dual action at opioid and dopamine receptors is of interest. Herein, we present nuclear magnetic resonance (NMR) spectroscopy and molecular dynamics simulation results for LENART01, an opioid-ranatensin hybrid peptide. Apart from molecular docking, protein-ligand interactions were also assessed in vitro using a receptor binding assay, which proved LENART01 to be bound to mu-opioid and dopamine receptors, respectively.
- Published
- 2024
- Full Text
- View/download PDF
99. Stabilizing Scaffold for Short Peptides Based on Knottins.
- Author
-
Beloborodov E, Iurova E, Sugak D, Rastorgueva E, Pogodina E, Fomin A, Viktorov D, Slesarev S, and Saenko Y
- Subjects
- Humans, Animals, Peptides chemistry, Peptides pharmacology, Cystine-Knot Miniproteins chemistry, Cystine-Knot Miniproteins pharmacology, Bombesin chemistry, Bombesin pharmacology
- Abstract
Background: Bombesin (BBN) is a short peptide with a high affinity for receptors that are expressed on the surface of various types of cancer cells. However, a full length BBN molecule has low in vivo stability., Objective: In our study, we propose the use of peptide toxins, derived from animal and plant toxins, as scaffold molecules to enhance the bioavailability and stability of bombesin. These peptides possess a unique structure known as an inhibitory cystine knot., Methods: We synthesized structures in which short bombesin was incorporated into various domains of arthropod and plant toxins using solid-phase peptide synthesis. The stability under different conditions was assessed through high-performance liquid chromatography, and binding to cell cultures expressing the bombesin receptor was analyzed. Additionally, toxicity to cell cultures was evaluated using fluorescence microscopy., Results: The data obtained demonstrated that placing the short peptide between the first and second cysteine residues in arachnid toxins results in increased in vitro stability and bioavailability, as well as low cytotoxicity., Conclusion: Arachnid toxins with an inhibitory cystine knot can be considered as a scaffold for increasing the stability of therapeutic peptides., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF
100. Differential expression of neuromedin B in cancers of the breast
- Subjects
Women -- Health aspects ,Bombesin ,Cancer ,Breast cancer ,Health ,Women's issues/gender studies - Abstract
2021 DEC 16 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.